[1]
|
D. Sanglard and F. C. Odds, “Resistance of Candida Species to Antifungal Agents: Molecular Mechanisms and Clinical Consequences,” Lancet Infectious Disease, Vol. 2, No. 2, 2002, pp. 73-85. doi:10.1016/S1473-3099(02)00181-0
|
[2]
|
M. M. Canuto and F. G. Rodero, “Antifungal Drug Resistance to Azoles and Polyenes,” Lancet Infectious Disease, Vol. 2, No. 9, 2002, pp. 550-63.
|
[3]
|
D. A. Said, E. Anaissie, O. Uzun, H. Pinzkowzki and S. Vartivarian, “The Epidemiology of Hematogenous Candidiasis Caused by Different Candida Species,” Clinical Infectious Disease, Vol. 24, No. 6, 1997, pp. 1122-1128.
doi:10.1086/513663
|
[4]
|
A. H. Groll and J. C. Gea-Banacloche, “Clinical Pharmacology of Antifungal Compounds,” Infectious Disease Clinics Of North America, Vol. 17, No. 1, 2003, pp. 159-191.
|
[5]
|
A. Kettani, Z. H. Belkhadir, A. Mosadik, A. Faroudy, A. Ababou, A. Lazreq and A. Sbihi, “Traitement Antifongique des Candidoses Systémiques en réAnimation,” Journal de Mycologie Médicale, Vol. 16, No. 1, 2006, pp. 16-25.
|
[6]
|
J. P. Adler-Moore, J. A. Olson and R. T. Proffitt, “Alternative Dosing Regimens of Liposomal Amphotericin B (AmBisome) Effective in Treating Murine Systemic Candidiasis,” Journal of Antimicrobial Chemotherapy, Vol. 54, No. 6, 2004, pp. 1096-1102. doi:10.1093/jac/dkh460
|
[7]
|
B. Blanchet, E. Huet, A. Astier and A. Hulin, “Suivie Thérapeutique des Médicaments Antifongiques. Pharmacocinétique des Médicaments Infectieux,” Revue Fran?aise des Laboratoires, Vol. 2004, No. 365, 2004, pp. 39-47.
|
[8]
|
M. Mariné, R. Espada, J. Torrado, F. J. Pastor and J. Guarro, “Efficacy of a New Formulation of Amphotericin B in a Murine Model of Disseminated Infection by Candida Glabrata,” Journal of Antimicrobial Chemotherapy, Vol. 61, No. 4, 2008, pp. 1-4.
|
[9]
|
F. Gaboriau, M. Cheron, C. Petit and J. Bolard, “Heat-In- duced Superaggregation of Amphotericin B Reduces Its in Vitro Toxicity: A New Way to Improve Its Therapeutic Index,” Antimicrobial Agents and Chemotherapy, Vol. 41, No. 11, 1997, pp. 2345-2351.
|
[10]
|
C. Petit, M. Cheron, V. Joly, J. M. Rodrigues, J. Bolard and F. Gaboriau, “In-Vivo Therapeutic Efficacy in Experimental Murine Mycoses of a New Formulation of Deoxycholate-Amphotericin B Obtained by Mild Heating,” Journal of Antimicrobial Chemotherapy, Vol. 42, No. 6, 1998, pp. 779-785. doi:10.1093/jac/42.6.779
|
[11]
|
R. Espada, S. Valdespina, M. A. Dea, G. Molero, M. P. Ballesteros, F. Bola and J. J. Torrado, “In Vivo Distribution and Therapeutic Efficacy of a Novel Amphotericin B Poly-Aggregated Formulation,” Journal of Antimicrobial Chemotherapy, Vol. 61, No. 5, 2008, pp. 1-7.
|
[12]
|
L. Belkherroubi-Sari, Z. Boucherit, M. Chéron, K. Bou- cherit, M. Benyoucef and S. Belbraouet, “Modulation of the Polyene Antibiotic Amphotericin B Selective Toxicity by pH Change of the Stock Solutions,” African Journal of Microbiology Research, Vol. 2, 2008, pp. 242-246
|
[13]
|
M. Kleinberg, “What Is the Current and Future Status of Conventional Amphotericin B?” International Journal of Antimicrobial Agents, Vol. 27, No. 1, pp. 12-16.
doi:10.1016/j.ijantimicag.2006.03.013
|